ClinicalTrials.gg
RecruitingNCT07903064Updated Nov 12, 2026

A Phase 1, First-in-Human Trial of BLN-481in Healthy Adult Participants

A Phase 1 interventional study of Placebo and BLN-481 in Healthy Volunteers (no Disease Condition Under Study), sponsored by Beeline Medicines Corporation. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Beeline Medicines Corporation · Phase 1, Interventional, and Basic science

Updated Nov 12, 2026Now RecruitingFirst site in Australia+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This Phase 1 first-in-human study will evaluate BLN-481 in healthy adults. Participants will receive BLN-481 or placebo. Part 1 evaluates single ascending intravenous (IV) doses (SAD) and optional subcutaneous (SC) doses. Part 2 evaluates multiple ascending subcutaneous doses (MAD). The main purpose is to assess safety and tolerability. The study will also evaluate how BLN-481 moves through the body, whether anti-drug antibodies (ANA) develop, and pharmacodynamic (PD) effects.

Read the detailed description

BLN-481 is a monoclonal allosteric blocking antibody targeting IL-18 receptor beta (IL-18Rβ). The study is randomized, double-blind, placebo-controlled, and uses sentinel dosing in each cohort. Part 1 includes sequential single-dose cohorts; Part 2 includes sequential multiple-dose cohorts administered every 2 (Q2W) or 4 (Q4W) weeks for three total doses. Dose escalation decisions will be based on review of available safety, tolerability, and pharmacokinetic (PK) data by the Dose Escalation Committee. Approximately 104 healthy adult participants are planned.

02

Conditions studied

  • Healthy Volunteers (no Disease Condition Under Study)

Keywords

  • IL-18Rβ
  • BLN-481
  • Healthy volunteers
  • First-in-human
  • Single Ascending Dose
  • Multiple Ascending Dose
03

In context

Lead sponsor

Beeline Medicines Corporation is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide
  • Healthy adults 18-55 years, inclusive
  • (BMI) between 18 and 32 kg/m2 inclusive at screening
  • Willing and able to comply with visits, restrictions, laboratory tests, requirements, and study procedure
  • Meets protocol-defined reproductive and contraception requirements

Exclusion criteria

Exclusion Criteria:

  • Inability to comply with trial protocol and lifestyle restrictions
  • medical history, examination, vital-sign, , laboratory, or spirometry findings.
  • Active or relevant infection, including protocol-defined , , , tuberculosis, or Treponema pallidum findings.
  • Significant allergy, drug reaction, treated asthma/reactive airway disease, hypercoagulation, thrombotic disease, or recent substance abuse.
  • Pregnancy, breastfeeding, or planned pregnancy/breastfeeding during the study.
  • Prohibited recent medication, , surgery (planned or within 12 weeks of Day -1), blood donation/transfusion, tobacco/nicotine use, or inability to comply with study restrictions.
  • Participation in another study or other protocol-defined exclusion.
  • The participant has a percent predicted that doesn't meet study requirements
  • Prisoners or participants who are incarcerated
  • Donated blood within 30 days of check-in
  • Blood transfusion within 8 weeks of check-in
  • Inability to be venipunctured and/or tolerate venous access
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    BLN-481

    Part 1 (SAD): Single IV doses in Cohorts 1A-1E at planned doses of 10, 30, 100, 300, and 900 mg. Optional Cohort 1X may receive a single IV or SC dose; optional Cohorts 1Y and 1Z may receive a single SC dose, with dose levels to be determined. Each Part 1 cohort includes up to 8 participants randomized 6:2 to BLN-481: placebo. Part 2 (MAD): SC dosing in Cohort 2A at 50 mg Q2W, Cohort 2B at 150 mg Q2W, and Cohort 2C at 450 mg Q2W or Q4W, for 3 total doses. Optional Cohort 2D may receive a dose to be determined Q2W or Q4W for 3 total doses. Each Part 2 cohort includes up to 10 participants randomized 8:2 to BLN-481: placebo.

    Drug: BLN-481

  • Placebo comparator
    Placebo

    Matching placebo is administered by the same route and on the same schedule as the assigned BLN-481 cohort. Part 1 placebo is administered as a single IV infusion or SC injection. Part 2 placebo is administered SC Q2W or Q4W for 3 total doses. Each cohort uses blinded sentinel dosing: 1 participant assigned to BLN-481 and 1 participant assigned to placebo are dosed first before the remaining cohort participants.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Matching placebo is administered by the same route and on the same schedule as the assigned BLN-481 cohort. Part 1 placebo is administered as a single IV infusion or SC injection. Part 2 placebo is administered SC Q2W or Q4W for 3 total doses. Each cohort uses blinded sentinel dosing: 1 participant assigned to BLN-481 and 1 participant assigned to placebo are dosed first before the remaining cohort participants.

    Also known as: Placebo for BLN-481

  • DrugBLN-481

    Part 1 (SAD): Single IV doses in Cohorts 1A-1E at planned doses of 10, 30, 100, 300, and 900 mg. Optional Cohort 1X may receive a single IV or SC dose; optional Cohorts 1Y and 1Z may receive a single SC dose, with dose levels to be determined. Each Part 1 cohort includes up to 8 participants randomized 6:2 to BLN-481: placebo. Part 2 (MAD): SC dosing in Cohort 2A at 50 mg Q2W, Cohort 2B at 150 mg Q2W, and Cohort 2C at 450 mg Q2W or Q4W, for 3 total doses. Optional Cohort 2D may receive a dose to be determined Q2W or Q4W for 3 total doses. Each Part 2 cohort includes up to 10 participants randomized 8:2 to BLN-481: placebo.

06

What researchers measure

Primary outcomes

  1. Participant incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Summary of TEAEs and SAEs

    Time frame: Up to 24 weeks

  2. Clinically significant abnormalities in safety laboratory tests

    Number of participants with clinically significant abnormalities in protocol-specified clinical laboratory assessments, including hematology, coagulation, chemistry, and urinalysis.

    Time frame: Up to approximately 20 weeks

  3. Clinically significant changes in spirometry for the 900mg IV Cohort in Part 1 (FEV1)

    Change from baseline in FEV1 measured by spirometry in participants in the highest planned dose cohort (900 mg IV). FEV1 is normalized using the standards specified in the protocol.

    Time frame: Baseline through Day 92 (approximately 13 weeks)

  4. Clinically significant abnormalities in Vital Signs

    Number of participants with clinically significant abnormalities in protocol-specified vital sign assessments, including blood pressure, heart rate, respiratory rate, body temperature, and pulse oximetry.

    Time frame: Up to approximately 20 weeks

  5. Clinically Significant Abnormalities in 12-Lead ECG QTcF Interval

    Number of participants with clinically significant abnormalities in QT interval corrected for heart rate using Fridericia's formula (QTcF), as assessed by 12-lead ECG.

    Time frame: Up to approximately 20 weeks

  6. Clinically significant abnormalities on Physical Examination

    Number of participants with clinically significant abnormalities identified during protocol-specified physical examinations. Complete physical examinations include assessment of the head, eyes, ears, nose, and throat (HEENT); neck; chest; lungs; abdomen; musculoskeletal, neurological, dermatological, cardiovascular, and peripheral vascular systems; and any areas of note identified during the daily review of adverse events. Targeted physical examinations are symptom-directed.

    Time frame: Up to approximately 20 weeks

  7. Clinically significant changes in spirometry from Baseline in Forced Vital Capacity (FVC) in the 900 mg IV Cohort

    Change from baseline in FVC measured by spirometry in participants in the highest planned dose cohort (900 mg IV).

    Time frame: Baseline through Day 92 (approximately 13 weeks)

  8. Clinically significant changes in spirometry from Baseline in FEV1/FVC Ratio in the 900 mg IV Cohort

    Change from baseline in the ratio of FEV1 to FVC measured by spirometry in participants in the highest planned dose cohort (900 mg IV).

    Time frame: Baseline through Day 92 (approximately 13 weeks)

  9. Clinically significant changes in spirometry from Baseline in Forced Expiratory Flow at 25% to 75% of FVC (FEF25-75%) in the 900 mg IV Cohort

    Change from baseline in FEF25-75% measured by spirometry in participants in the highest planned dose cohort (900 mg IV).

    Time frame: Baseline through Day 92 (approximately 13 weeks)

Secondary outcomes

  1. Part 1 serum pharmacokinetic parameters (Cmax) of BLN-481

    Maximum observed serum concentration of BLN-481.

    Time frame: Up to 13 weeks

  2. Part 1 serum pharmacokinetic parameters (Tmax) of BLN-481

    Time of maximum observed serum concentration of BLN-481.

    Time frame: Up to 13 weeks

  3. Part 1 serum pharmacokinetic parameters [AUC(0-T)] of BLN-481

    Area under the serum concentration-time curve from time 0 to the time of the last quantifiable concentration.

    Time frame: Up to 13 weeks

  4. Part 1 serum pharmacokinetic parameters [AUC(INF)] of BLN-481

    Area under the serum concentration-time curve from time 0 extrapolated to infinite time.

    Time frame: Up to 13 weeks

  5. Part 1 serum pharmacokinetic parameters (T-HALF) of BLN-481

    Terminal elimination half-life of BLN-481.

    Time frame: Up to 13 weeks

  6. Part 1 serum pharmacokinetic parameters Total Body Clearance (CLT) of BLN-481

    Total body clearance of BLN-481 following intravenous administration.

    Time frame: Up to 13 Weeks

  7. Incidence of anti-drug antibodies (ADA) to BLN-481

    Summary of ADA incidence by treatment arm and study part.

    Time frame: Up to approximately 20 weeks

  8. Part 1 serum pharmacokinetic parameters T(CLT/F) of BLN-481

    Apparent total body clearance of BLN-481 following subcutaneous administration.

    Time frame: Up to 13 weeks

  9. Part 1 serum pharmacokinetic parameters (Vz) of BLN-481

    Volume of distribution of the terminal phase of BLN-481 following intravenous administration.

    Time frame: Up to 13 weeks

  10. Part 1 serum pharmacokinetic parameters (Vz/F) of BLN-481

    Apparent volume of distribution of the terminal phase of BLN-481 following subcutaneous administration.

    Time frame: Up to 13 weeks

  11. Part 1 serum pharmacokinetic parameters Absolute Bioavailability of BLN-481 Following Subcutaneous Administration

    Absolute bioavailability of BLN-481 following a single subcutaneous administration.

    Time frame: Up to 13 weeks

  12. Part 2 serum pharmacokinetic parameters (Cmax) of BLN-481

    Time of maximum observed serum concentration of BLN-481.

    Time frame: Up to 20 weeks

  13. Part 2 serum pharmacokinetic parameters (Tmax) of BLN-481

    Time of maximum observed serum concentration of BLN-481.

    Time frame: Up to 20 weeks

  14. Part 2 serum pharmacokinetic parameters [AUC(TAU)] of BLN-481

    Area under the serum concentration-time curve within a dosing interval.

    Time frame: Up to 20 weeks

  15. Part 2 serum pharmacokinetic parameters (Ctrough) of BLN-481

    Trough observed serum concentration of BLN-481.

    Time frame: Up to 20 weeks

  16. Part 2 serum pharmacokinetic parameters (T-HALF) of BLN-481

    Terminal elimination half-life of BLN-481.

    Time frame: Up to 20 weeks

  17. Part 2 serum pharmacokinetic parameters (AI_AUC) of BLN-481

    Ratio of AUC(TAU) after the third dose to AUC(TAU) after the first dose.

    Time frame: Up to 20 weeks

  18. Part 2 serum pharmacokinetic parameters (AI_Cmax) of BLN-481

    Ratio of Cmax after the third dose to Cmax after the first dose.

    Time frame: Up to 20 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participate data will not be shared as this phase 1 study is explicitly designed to evaluate the safety, tolerability, and initial pharmacokinetics. The Sponsor intends to report study results in aggregate form, as applicable.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Nov 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2026
First posted
Oct 29, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Nov 24, 2027
CompletionEst.
Nov 24, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
1 site added — first site in Australia
Show site
  • Nucleus Network · Herston, Australia
Nov 12, 2026
Start date
Oct 12, 2026→Oct 30, 2026
Nov 12, 2026
Registered
First appeared on the registry
Oct 29, 2026
Show all 2 updates
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Australia
    Show site
    • Nucleus Network · Herston, Australia
    Start date Oct 12, 2026→Oct 30, 2026
  2. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07903064
Lead sponsor
Beeline Medicines Corporation
Collaborators
Nucleus Network Ltd
Responsible party
Sponsor
First posted
Oct 29, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Nov 24, 2027 (estimated)
Completion
Nov 24, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Study Director
Contact
medinfo@beelinemedicines.com
+1-617-885-8290
Jerome Hanna
study director · Beeline Medicines Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion